Headquartered in Pleasanton, California, Roche Molecular Diagnostics (RMD) is a business area of Roche Diagnostics (Basel, Switzerland) that develops, manufactures and supplies a wide array of innovative medical diagnostic products, services, tests, platforms and technologies. With its broad portfolio of oncology, virology, microbiology and blood screening tests, RMD’s clients include researchers, physicians, patients, hospitals, laboratories and blood banks around the world.
The business was founded in the early 1990s following the acquisition of the revolutionary, Nobel-prize winning Polymerase Chain Reaction Technology (PCR). PCR quickly replicates a single specific fragment of DNA or RNA to quantities sufficient for accurate laboratory analysis.
RMD’s diagnostic tests and automated platforms are focused on the following areas:
Viral infections rank among the biggest causes of death worldwide. With HIV or hepatitis viruses, early detection and viral load monitoring are crucial to managing disease treatment, as well as in identifying strains of the virus that have developed drug resistance. RMD provides automated tests to directly detect and quantify viral load of hepatitis B and C, HIV, along with tests for cytomegalovirus (CMV).
Each year, more than 80 million units of donated blood are stored and distributed worldwide. RMD provides blood banks with highly sensitive and automated real-time PCR tests to detect HIV, hepatitis B & C, and West Nile Virus, helping to ensure that blood supplies are safe and free from serious infectious diseases before they are used.
HPV and CT/NG
RMD provides tests for the detection of Human Papillomavirus (HPV), Chlamydia and Gonorrhea (CT/NG), as well as genotyping of HPV to identify high-risk HPV types known to be associated with progression to cervical cancer.
Genomics and Oncology
Cancer is an extremely complex disease, with many subtypes and variations that can influence disease progression and response to therapy. RMD’s gene-based tests help physicians better understand specific biological factors that help them select the right therapy. These tests detect clinically relevant genetic variations in the patient or disease that influence disease progression and treatment selection.
A high number of patients entering hospitals acquire an infection. RMD’s tests rapidly detect disease-causing pathogens such as tuberculosis as well as fungi and bacteria such as MRSA that can lead to life-threatening sepsis.
Point of Care
The new cobas Liat system is a compact, innovative real-time PCR platform designed for on-demand testing, enabling confidence at the point of care, in the physicians clinic or the laboratory, to aid treatment decisions. Current assays for the cobas Liat system include tests for Influenza A and B, and Strep A.